Binge-eating disorder is characteri...

Binge-eating disorder is characterized by dint of uncontrolled consumption of large amounts of rations The differentiating characteristic between this disorder and bulimia nervosa is that patients do not run after binge eating with compensatory behaviors as it was as self-induced vomiting. Binge-eating disorder is for the use of all in patients who seek treatment for obesity. ones with this disorder have higher rates of comorbid psychiatric disorders, especially depression. Treatment goals for patients who put up with from binge-eating disorder include cessation of binge eating, weight reduction, and improvement in any comorbid psychiatric disorder. Part of the multidisciplinary treatment of binge-eating disorder includes pharmacotherapy. Prior studies have shown that selective serotonin reuptake inhibitors have been prosperous in reducing the frequency of binge eating, if it were not that they do not promote weight los A novel serotonin and norepinephrine reuptake inhibitor, sibutramine, has been shown to be effective in weight reduction and maintenance programs in short- and long-term studies. Appolinario and associates evaluated the efficacy and safety of sibutramine in the treatment of patients with binge-eating disorder.

The trial was a randomized, double-blind, placebo-controlled thought of patients who met the criteria for binge-eating disorder in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed and also met the definition of obesity based upon their body mass index. Patients who met the inclusion criteria were randomly assigned to receive sibutramine in a dosage of 15 mg by day or placebo for 12 weeks. Patients were assessed at baseline and each two weeks during the reflection Binge frequency, which was defined as the number of days with binge-eating episodes in the past week, was the primary consequence measure. Other outcome measures included scores onward the Binge Eating Scale and the Beck Depression Inventory, weight changes, and treatment answer (remission or response). Safety and tolerability of the medication also were evaluated.

Sixty patients were randomized to cogitation groups; 23 in the sibutramine form into groups and 25 in the placebo arrange completed the study. There was a significant reduction in the number of binge-eating days in the sibutramine cluster compared with the placebo collection The treatment group also missed substantially more weight than the placebo cluster With regard to scores forward the Binge Eating Scale and the Beck Depression Inventory, the sibutramine form into groups had significantly lower scores than the placebo cluster The main adverse reactions in the sibutramine clump were dry mouth and constipation. solitary two patients in the active treatment assemblage withdrew from the study because of adverse issues of the medication.

The authors end that sibutramine is an effective medication in the treatment of obese patients with binge-eating disorders. In addition, this medication is well tolerated, with not many adverse effects. Sibutramine therapy addresses the three main goals of treating patients with binge-eating disorder: binge eating, weight reduction, and treating comorbid psychiatric conditions.

Appolinario JC et al. A randomized, double-blind, placebo-controlled meditation of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry November 2003;60:1109-16

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group